Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TOP2A | P11388 | 3/20 | 0.35 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 6/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | ACACB | O00763 | 1/20 | 0.30 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17068618 | 0.92 | HPGD (0.35) | TOP2AAKR1C3HPGDALDH1A1KDM4E | |
| SCHEMBL17068566 | 0.82 | L3MBTL1 (0.33) | CYP1A2CYP2C19 | |
| SCHEMBL17068571 | 0.81 | — | — | |
| SCHEMBL17068430 | 0.81 | KDM4E (0.32) | ALDH1A1KDM4EFFAR4KMT2A | |
| SCHEMBL17068508 | 0.81 | ALDH1A1 (0.33) | ALDH1A1KDM4ECYP1A2MAPTCYP2C9 | |
| SCHEMBL18006914 | 0.80 | TOP2A (0.34) | TOP2AAKR1C3HPGDALDH1A1KDM4E | |
| SCHEMBL17068598 | 0.78 | LTB4R (0.34) | CYP1A2CYP2C19 | |
| SCHEMBL17068563 | 0.78 | — | — | |
| SCHEMBL17068570 | 0.77 | SLC6A4 (0.33) | — | |
| SCHEMBL17068611 | 0.76 | HTR2A (0.34) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9523038-B2 | Dihydropyran compound, liquid crystal composition and liquid crystal display device | JNC CORPORATION (JP) | 2016-12-20 | — | — | US | disclosed |
| US-9523038-B2 | Dihydropyran compound, liquid crystal composition and liquid crystal display device | JNC CORPORATION (JP) | 2016-12-20 | — | — | US | disclosed |
| US-20150252264-A1 | DIHYDROPYRAN COMPOUND, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | JNC PETROCHEMICAL CORPORATION (JP) | 2015-09-10 | — | — | US | disclosed |
| US-20150252264-A1 | DIHYDROPYRAN COMPOUND, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | JNC PETROCHEMICAL CORPORATION (JP) | 2015-09-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150252264-A1 | DIHYDROPYRAN COMPOUND, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | DRD1, CNKSR1, DRG1 | TOP2A 977/4885AKR1C3 1771/4885HPGD 3243/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.